Screener
Kura Oncology KURA CapEx
CapEx at other companies
Other financials
Where this comes from
Reported directly by Kura Oncology in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.
The source filing: Kura Oncology’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-219481
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Investing Activities | ||
| Purchases of short-term investments | (171,601) | (268,714) |
| Maturities of short-term investments | 147,498 | 167,597 |
| Purchases of property and equipment | (128) | (292) |
| Net cash used in investing activities | (24,231) | (101,409) |
| Financing Activities | ||
| Proceeds from issuance of stock under equity plans | 69 | 143 |
| Net cash provided by financing activities | 69 | 143 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Kura Oncology's capex?
- Kura Oncology (KURA) reported capex of $128K in Q1 2026.
- How has Kura Oncology's capex changed year-over-year?
- Kura Oncology's capex decreased by 56.2% year-over-year, from $292K to $128K.
- What is the long-term trend for Kura Oncology's capex?
- Over 4 years (2021 to 2025), Kura Oncology's capex has grown at a 55.1% compound annual growth rate (CAGR), from $1.15M to $6.64M.
- What does capex mean?
- Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.
Ask your AI about Kura Oncology's capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude